Therapies for multiple sclerosis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Multiple sclerosis (MS) is an idiopathic inflammatory demyelinating disease of the central nervous system. It is one of the leading causes of neurologic disability, particularly in young adults, and is presumed to be autoimmune. This chapter discusses the evidence supporting the use of the MS therapies. It presents clinical scenarios for the following: clinically isolated syndrome, interferon-beta and glatiramer acetate for relapsing-remitting multiple sclerosis, natalizumab and fingolimod, teriflunomide and dimethyl fumarate, secondary progressive MS, primary progressive MS, and dalfampridine. Disease-modifying therapies are all effective for reducing the annual relapse rate of relapsing-remitting disease (RRMS). In summary, substantial progress has been made toward halting inflammatory disease activity in RRMS but future therapies will need to focus on SPMS and PPMS in order to meet the major unmet needs, particularly accumulation of neurological disability, of patients with multiple sclerosis.

Original languageEnglish (US)
Title of host publicationEvidence-Based Neurology
Subtitle of host publicationManagement of Neurological Disorders: Second Edition
PublisherWiley Blackwell
Pages209-218
Number of pages10
ISBN (Electronic)9781119067344
ISBN (Print)9780470657782
DOIs
StatePublished - Dec 11 2015

Fingerprint

Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Interferon-beta
Demyelinating Diseases
Therapeutics
Nervous System
Young Adult
Central Nervous System
Recurrence

Keywords

  • Clinically isolated syndrome
  • Dalfampridine
  • Dimethyl fumarate
  • Fingolimod
  • Glatiramer acetate
  • Interferon-beta
  • Multiple sclerosis
  • Natalizumab
  • Teriflunomide

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Thaera, G., & Wingerchuk, D. M. (2015). Therapies for multiple sclerosis. In Evidence-Based Neurology: Management of Neurological Disorders: Second Edition (pp. 209-218). Wiley Blackwell. https://doi.org/10.1002/9781119067344.ch20

Therapies for multiple sclerosis. / Thaera, Greg; Wingerchuk, Dean Marko.

Evidence-Based Neurology: Management of Neurological Disorders: Second Edition. Wiley Blackwell, 2015. p. 209-218.

Research output: Chapter in Book/Report/Conference proceedingChapter

Thaera, G & Wingerchuk, DM 2015, Therapies for multiple sclerosis. in Evidence-Based Neurology: Management of Neurological Disorders: Second Edition. Wiley Blackwell, pp. 209-218. https://doi.org/10.1002/9781119067344.ch20
Thaera G, Wingerchuk DM. Therapies for multiple sclerosis. In Evidence-Based Neurology: Management of Neurological Disorders: Second Edition. Wiley Blackwell. 2015. p. 209-218 https://doi.org/10.1002/9781119067344.ch20
Thaera, Greg ; Wingerchuk, Dean Marko. / Therapies for multiple sclerosis. Evidence-Based Neurology: Management of Neurological Disorders: Second Edition. Wiley Blackwell, 2015. pp. 209-218
@inbook{45ea05f0c50345e889550eb0155c9eee,
title = "Therapies for multiple sclerosis",
abstract = "Multiple sclerosis (MS) is an idiopathic inflammatory demyelinating disease of the central nervous system. It is one of the leading causes of neurologic disability, particularly in young adults, and is presumed to be autoimmune. This chapter discusses the evidence supporting the use of the MS therapies. It presents clinical scenarios for the following: clinically isolated syndrome, interferon-beta and glatiramer acetate for relapsing-remitting multiple sclerosis, natalizumab and fingolimod, teriflunomide and dimethyl fumarate, secondary progressive MS, primary progressive MS, and dalfampridine. Disease-modifying therapies are all effective for reducing the annual relapse rate of relapsing-remitting disease (RRMS). In summary, substantial progress has been made toward halting inflammatory disease activity in RRMS but future therapies will need to focus on SPMS and PPMS in order to meet the major unmet needs, particularly accumulation of neurological disability, of patients with multiple sclerosis.",
keywords = "Clinically isolated syndrome, Dalfampridine, Dimethyl fumarate, Fingolimod, Glatiramer acetate, Interferon-beta, Multiple sclerosis, Natalizumab, Teriflunomide",
author = "Greg Thaera and Wingerchuk, {Dean Marko}",
year = "2015",
month = "12",
day = "11",
doi = "10.1002/9781119067344.ch20",
language = "English (US)",
isbn = "9780470657782",
pages = "209--218",
booktitle = "Evidence-Based Neurology",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Therapies for multiple sclerosis

AU - Thaera, Greg

AU - Wingerchuk, Dean Marko

PY - 2015/12/11

Y1 - 2015/12/11

N2 - Multiple sclerosis (MS) is an idiopathic inflammatory demyelinating disease of the central nervous system. It is one of the leading causes of neurologic disability, particularly in young adults, and is presumed to be autoimmune. This chapter discusses the evidence supporting the use of the MS therapies. It presents clinical scenarios for the following: clinically isolated syndrome, interferon-beta and glatiramer acetate for relapsing-remitting multiple sclerosis, natalizumab and fingolimod, teriflunomide and dimethyl fumarate, secondary progressive MS, primary progressive MS, and dalfampridine. Disease-modifying therapies are all effective for reducing the annual relapse rate of relapsing-remitting disease (RRMS). In summary, substantial progress has been made toward halting inflammatory disease activity in RRMS but future therapies will need to focus on SPMS and PPMS in order to meet the major unmet needs, particularly accumulation of neurological disability, of patients with multiple sclerosis.

AB - Multiple sclerosis (MS) is an idiopathic inflammatory demyelinating disease of the central nervous system. It is one of the leading causes of neurologic disability, particularly in young adults, and is presumed to be autoimmune. This chapter discusses the evidence supporting the use of the MS therapies. It presents clinical scenarios for the following: clinically isolated syndrome, interferon-beta and glatiramer acetate for relapsing-remitting multiple sclerosis, natalizumab and fingolimod, teriflunomide and dimethyl fumarate, secondary progressive MS, primary progressive MS, and dalfampridine. Disease-modifying therapies are all effective for reducing the annual relapse rate of relapsing-remitting disease (RRMS). In summary, substantial progress has been made toward halting inflammatory disease activity in RRMS but future therapies will need to focus on SPMS and PPMS in order to meet the major unmet needs, particularly accumulation of neurological disability, of patients with multiple sclerosis.

KW - Clinically isolated syndrome

KW - Dalfampridine

KW - Dimethyl fumarate

KW - Fingolimod

KW - Glatiramer acetate

KW - Interferon-beta

KW - Multiple sclerosis

KW - Natalizumab

KW - Teriflunomide

UR - http://www.scopus.com/inward/record.url?scp=85017991689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017991689&partnerID=8YFLogxK

U2 - 10.1002/9781119067344.ch20

DO - 10.1002/9781119067344.ch20

M3 - Chapter

AN - SCOPUS:85017991689

SN - 9780470657782

SP - 209

EP - 218

BT - Evidence-Based Neurology

PB - Wiley Blackwell

ER -